Synlogic (SYBX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The 2024 Annual Meeting will be held virtually on December 4, 2024, with voting on director election, executive compensation, and auditor ratification.
Stockholders as of November 1, 2024, are eligible to vote; multiple voting methods are available, including online, phone, and mail.
The Board recommends voting in favor of all proposals on the agenda.
Voting matters and shareholder proposals
Proposals include electing one Class III director (Nick Leschly) for a three-year term, an advisory vote on executive compensation, and ratification of KPMG LLP as auditor.
Shareholders may submit proposals for the 2025 meeting between August 6 and September 5, 2025.
Voting results will be published in a Form 8-K within four business days of the meeting.
Board of directors and corporate governance
The Board consists of six members, all deemed independent under Nasdaq rules.
Board committees include Audit, Compensation, Nominating and Governance, and Science & Technology, each with defined charters and independent members.
Board diversity is tracked and disclosed, with a matrix provided as of October 31, 2024.
The Board separates the roles of Chairman and Principal Executive Officer.
Latest events from Synlogic
- Restructured as a shell after discontinuing clinical programs, with sharply reduced expenses and a $1M net loss.SYBX
Q4 202512 Mar 2026 - Biopharma seeks $150M shelf offering after pivoting to strategic alternatives post-trial halt.SYBX
Registration Filing16 Dec 2025 - Amended filing allows flexible securities issuance and updates legal protections for management.SYBX
Registration Filing16 Dec 2025 - Net loss narrowed to $2.3M in Q3 2025 amid restructuring and strategic review.SYBX
Q3 202513 Nov 2025 - Annual Meeting to vote on directors, executive pay, new equity plan, and auditor ratification.SYBX
Proxy Filing12 Nov 2025 - Losses narrowed sharply after restructuring and trial discontinuation; strategic review ongoing.SYBX
Q2 20257 Aug 2025 - Lead program ended, costs cut, and strategic options under review with $19.4M cash on hand.SYBX
Q3 202413 Jun 2025 - Q2 net income reached $2.0M after restructuring; $20M cash remains as strategic options are explored.SYBX
Q2 202413 Jun 2025 - Discontinued lead program, restructured operations, and now pursuing strategic alternatives.SYBX
Q4 20249 Jun 2025